Yun Zhong

The European Rett Syndrome Conference gets underway Friday in Finland. Among the presenters: a New York-based micro-cap biotech that has an investigational asset to treat Rett syndrome in its pipeline.   Anavex Life Sciences Corp (NASDAQ: AVXL), founded in 2006, is a biotech that focuses...

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has an extensive portfolio of novel therapies for rare diseases with a focus on lysosomal storage disorders, according to Janney Montgomery Scott.  The Analyst Janney's Yun Zhong initiated coverage of Amicus Therapeutics with a Buy rating and $...

Insys Therapeutics Inc (NASDAQ: INSY), which specializes in painkillers and synthetic cannabinoid drugs, reported Thursday after the close with a sharp decline in revenue and a wider-than-expected loss in the fourth quarter. The Analysts Janney analyst Yun Zhong reiterated a Buy...

Sarepta Therapeutics Inc (NASDAQ: SRPT) reported fourth-quarter results Wednesday alongside positive results for its muscular dystrophy gene therapy candidate. The Analysts Janney analyst Yun Zhong reiterated a Buy rating on Sarepta with a $200 fair value estimate. Cantor Fitzgerald analyst...

With a blooming cannabis portfolio, an EpiPen alternative and a potent solution to opioid overdoses, Insys Therapeutics Inc (NASDAQ: INSY) is claiming space in some of biotech’s hottest segments. Some on the Street see “significant upside potential.” The Rating Janney analyst Yun...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market.  Sarepta shares were down 5 percent at the start of the week against a biotech index that was up 3 percent after the...

As Insys Therapeutics Inc (NASDAQ: INSY) shifts from opioid therapies to cannabinoids and spray technology, one analyst sees an opportunity to buy in. The Rating Janney analyst Yun Zhong assumed coverage with a Buy rating and cut his price target from $16 to $11. The Thesis Insys forecasted at...

Shares of bluebird bio Inc. (NASDAQ: BLUE) surged over 13 percent last week as the company announced plans to release abstracts at the American Society of Hematology meeting in December. The Analyst Janney analyst Yun Zhong upgraded bluebird from Neutral to Buy and maintained a $170 price...

Nightstar Therapeutics PLC (NASDAQ: NITE) leads the market in adeno-associated virus gene therapy for the treatment of inherited retinal disorders, according to a bullish Janney analyst.   The Analysts Analyst Yun Zhong initiated coverage of Nightstar with a Buy rating and $34 price...

Selecta Biosciences Inc (NASDAQ: SELB) shares plummeted in November 2017 from the $20 level and have yet to recover. The stock should not only recoup all of its losses, but trade at new all-time highs, according to Janney.  The Analyst Janney's Yun Zhong initiated coverage of Selecta...

SUMMIT THERAPEU/S ADR (NASDAQ: SMMT) is conducting clinical trials for Duchenne muscular dystrophy, or DMD, and clostridium difficile infection, or CDI. The Analyst Janney analyst Yun Zhong initiated coverage of Summit Therapeutics with a Buy rating and $27 fair value estimate. The Thesis...

Uniqure NV (NASDAQ: QURE) shares slid 22 percent in two weeks with no fundamental changes, prompting a Janney analyst to recommend buying the dip.  The Analyst Janney analyst Yun Zhong reiterated a Buy rating on the shares of Uniqure and increased the fair value estimate from $25 to $30....

Bluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer, released "highly encouraging" clinical data in late 2017, according to Janney. But that doesn't mean investors should be aggressive buyers...